Wealth Effects LLC Sells 24,833 Shares of Humacyte, Inc. (NASDAQ:HUMA)

by · The Cerbat Gem

Wealth Effects LLC reduced its position in Humacyte, Inc. (NASDAQ:HUMA – Free Report) by 20.5% in the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 96,567 shares of the company’s stock after selling 24,833 shares during the quarter. Wealth Effects LLC owned approximately 0.06% of Humacyte worth $165,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds have also recently made changes to their positions in the company. Columbia Advisory Partners LLC purchased a new stake in shares of Humacyte during the 1st quarter valued at approximately $27,000. Hamilton Lane Advisors LLC bought a new stake in Humacyte during the 1st quarter valued at $37,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its position in shares of Humacyte by 85.2% during the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 202,825 shares of the company’s stock worth $1,024,000 after acquiring an additional 93,283 shares in the last quarter. Waverly Advisors LLC lifted its position in shares of Humacyte by 331.9% during the fourth quarter. Waverly Advisors LLC now owns 274,579 shares of the company’s stock worth $1,387,000 after acquiring an additional 211,009 shares in the last quarter. Finally, Woodline Partners LP boosted its holdings in shares of Humacyte by 235.7% in the fourth quarter. Woodline Partners LP now owns 2,848,802 shares of the company’s stock worth $14,386,000 after acquiring an additional 2,000,268 shares during the period. 44.71% of the stock is currently owned by institutional investors.

Insider Activity

In other news, CFO Dale A. Sander bought 20,000 shares of the business’s stock in a transaction on Thursday, April 10th. The stock was acquired at an average price of $1.53 per share, with a total value of $30,600.00. Following the completion of the purchase, the chief financial officer now directly owns 40,600 shares in the company, valued at $62,118. This represents a 97.09% increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Also, Director Kathleen Sebelius purchased 50,000 shares of Humacyte stock in a transaction on Tuesday, April 8th. The shares were acquired at an average price of $1.32 per share, for a total transaction of $66,000.00. Following the completion of the transaction, the director now directly owns 91,207 shares of the company’s stock, valued at approximately $120,393.24. The trade was a 121.34% increase in their ownership of the stock. The disclosure for this purchase can be found here. In the last quarter, insiders have purchased 83,993 shares of company stock worth $118,224. 5.10% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes

HUMA has been the topic of a number of analyst reports. D. Boral Capital reiterated a “buy” rating and set a $25.00 price objective on shares of Humacyte in a research note on Monday, June 9th. HC Wainwright began coverage on Humacyte in a report on Wednesday, May 14th. They set a “buy” rating and a $4.00 target price for the company. Benchmark lowered their price target on shares of Humacyte from $17.00 to $14.00 and set a “buy” rating on the stock in a report on Wednesday, May 14th. Finally, Wall Street Zen lowered shares of Humacyte from a “hold” rating to a “sell” rating in a research report on Saturday, June 14th. One analyst has rated the stock with a sell rating, one has issued a hold rating, six have given a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $11.71.

Read Our Latest Report on HUMA

Humacyte Stock Performance

NASDAQ:HUMA opened at $2.22 on Friday. The stock has a market cap of $344.37 million, a P/E ratio of -3.22 and a beta of 2.00. The company has a quick ratio of 3.28, a current ratio of 3.68 and a debt-to-equity ratio of 0.36. The business’s 50-day moving average price is $2.05 and its two-hundred day moving average price is $3.02. Humacyte, Inc. has a twelve month low of $1.15 and a twelve month high of $9.79.

Humacyte (NASDAQ:HUMA – Get Free Report) last announced its earnings results on Tuesday, May 13th. The company reported ($0.10) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.19) by $0.09. The company had revenue of $0.52 million during the quarter, compared to analysts’ expectations of $0.46 million. As a group, equities analysts predict that Humacyte, Inc. will post -1.27 EPS for the current fiscal year.

About Humacyte

(Free Report)

Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.

Featured Stories

Want to see what other hedge funds are holding HUMA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Humacyte, Inc. (NASDAQ:HUMA – Free Report).